Clinical Trials
Spinal Cord Stimulation May Be A Boon For Stroke Patients
A small clinical trial has suggested that spinal cord stimulation may help stroke patients regain movement in their limbs and hands. In an article published in Nature Medicine, researchers detailed the experience of the first two people treated in...
Clinical Trials
HIV Simplified Treatment Options Effective In A Major Trial
As per the results of international research, which has the distinction of being the world’s first study into second-line human immunodeficiency virus- HIV therapy, 2 newer and simplified options in treatment are as effective as the standards of care...
Clinical Trials
Kidney Cancer Recurrence Can Be Gauged By DNA Mutations
One of the international studies on kidney cancer recurrence has found that physicians can forecast the likelihood of a disease returning by way of examining DNA mutations in the patients' tumours.
The study was undertaken by a team of 44...
Clinical Trials
Long Term Survival In Lung Cancer Can Be A Possibility
Final assessments of a Phase II trial for resectable non-small cell lung cancer found that 60% of patients who had gone on to receive the neoadjuvant nivolumab remained recurrence-free five years following surgery. Overall survival rates were also found...
Clinical Trials
Clinical Trials Diversity Continues To Be Area To Watch For
Biopharma companies as well as policymakers know the significance of assessing medical and drug products across a broad range of racial and ethnic universes so as to fully comprehend the medical effects on patients. This has indeed pushed the...
Clinical Trials
Gene Therapy Trials – A Word of Advice From FDA Officials
Representatives from the US FDA Center for Biologics Evaluation and Research Office of Tissues and Advanced Therapies have said that the gene therapy clinical trials depend on the nature of the disease being treated and that the diseases that...
Clinical Trials
Genenta expands pact with AGC Biologics to make cell therapy products for trials
Genenta Science, a clinical-stage biotechnology company, has entered into a development and manufacturing service agreement (MSA) with AGC Biologics S.p.A. to manufacture cell therapy lentivirus-based product for Genenta's ongoing clinical programmes.
AGC Biologics offers end-to-end global viral vector and cell...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
